Nevertheless, experimental approaches to inhibit LE/Lys-Chol transport targeting LDLR, NPC1 or StARD3 and small molecules inhibiting ORP proteins and Rab7 GTPase provide promise for therapeutic advances, and interfering with LDL-cholesterol distribution from LE/Lys could become a therapeutic target for cancer treatment and reduce the risk for metastasis or development of drug resistance. The gene discussed is STARD3; the disease is cancer.